An observational study in Carotid Stenosis, sponsored by Vibrant Medical Ltd.. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-01.
Sponsored by Vibrant Medical Ltd. · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 84 studies in Carotid Stenosis with a site in United States — 6 open to participants now, 13 under way, none of them phase 3. Carotid Stenosis · United States.
Among the 84 studies in Carotid Stenosis with a site in United States, this one is the 30th largest by planned enrollment of the 31 observational ones that give a count, is one of 2 that started in 2026, is one of 31 observational ones, reaches primary completion later than 6 of the 12 other live ones, and was the 83rd registered.
369 studies on the registry are indexed under Carotid Stenosis; 88 are open to participants now.
Browse Carotid Stenosis studies →6 of the 84 studies in Carotid Stenosis with a site in United States are open now. Recruiting first, the newest first:
InspireMD · Sites in United States
Ages 18–79
Mayo Clinic · Sites in United States
Ages 18+
VA Office of Research and Development · Sites in United States
Ages 18–89 · Healthy volunteers
University of California, San Diego · Sites in United States
Ages 18+
Dartmouth-Hitchcock Medical Center · Sites in United States
Ages 65+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 62 Carotid Stenosis studies recruiting now, 39 (63%) set no upper age limit and none (0%) stop at 75 or younger; 4 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
84 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 10 · Phase 3 7 · Phase 4 5
First in 1993; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 10 is below the median of 176 across 161 observational studies indexed under Carotid Stenosis.
Median enrollment 69 across the 53 interventional studies, 114 across the 31 observational. Of the 60 that completed or were terminated, 22 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 84 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Vibrant Medical Ltd. as lead sponsor.
Vibrant Medical Ltd. has 1 study filed under Carotid Stenosis — fewer than ten, so there is no comparison to draw.
3 of the studies in Carotid Stenosis with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07851389Vibrant Medical Ltd.A First-in-Human Feasibility Study of the Vibrant Stroke Detection Technology During Carotid Endarterectomies | 2027-03 |
| NCT04063709University of North Carolina, Chapel HillTranscutaneous ARFI Ultrasound for Differentiating Carotid Plaque With High Stroke Risk | 2027-08 |
| NCT05465122Mayo ClinicCREST-2 Long-term Observational Extension Study | 2027-08-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 84 studies in Carotid Stenosis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this observational study is to learn whether continuous carotid artery blood flow signals can be recorded reliably during surgery, and whether Vibrant Medical's analysis method can detect measurable changes in those signals, in adults undergoing elective carotid endarterectomy (CEA). During CEA, the surgeon temporarily clamps the internal carotid artery as a routine part of the operation. This produces a brief, controlled and fully reversible stop in blood flow that resembles the blood flow change seen in a large-vessel ischemic stroke.
The main questions it aims to answer are:
Participants will have their scheduled surgery as usual. During surgery, two legally marketed, FDA-cleared diagnostic ultrasound systems will record blood flow from the common carotid artery on each side of the neck, before clamping, during clamping and after the clamp is released, for about 20 to 30 minutes in total. The recordings are analyzed later and are not seen or used by the surgical team. No part of the surgery or anesthesia care is changed, and there are no study visits after surgery.
Background
In-hospital stroke is often recognized late, because patients may be sedated, anesthetized or otherwise unable to report symptoms, and there is currently no cleared device that continuously monitors carotid blood flow to flag a sudden change. Vibrant Medical is developing a wearable, non-invasive ultrasound sensor for this purpose. The element that is first-in-human in this study is Vibrant Medical's analysis method (wave-intensity and bilateral-asymmetry processing of carotid Doppler signals), which has previously been applied only to benchtop flow-phantom and in-vivo ovine data.
Carotid endarterectomy provides a controlled clinical model for this first human evaluation: the internal carotid artery clamp is applied and released by the surgeon as part of standard technique, producing a time-stamped, reversible reduction in carotid flow with no additional risk to the patient.
Study design
This is a prospective, single-center, single-arm, observational feasibility study at Tampa General Hospital / University of South Florida. Signals are acquired with two legally marketed, FDA-cleared Class II diagnostic ultrasound systems, one per side, each used within its cleared Peripheral Vessel indication.
Recording phases
No surgical step, including clamp timing, is delayed, modified or made contingent on the recordings. If a stable signal is not available when the surgeon is ready, the case proceeds unchanged and the phase is documented as missed.
Data collection and analysis
A study coordinator records time stamps of transducer placement, clamp application and release, and each recording phase on a case report form. Blood pressure, heart rate and the standard-of-care neuromonitoring data for the case are extracted from the anesthesia record and time-stamped to surgical events. Demographic and clinical variables (such as age, sex, BMI, surgical side and ASA class) are abstracted from the medical record. Recordings are exported and analyzed offline by Vibrant Medical research software labeled For Research Use Only; no output is available to the clinical team. Results are summarized descriptively; this feasibility study is not powered for hypothesis testing.
Adult patients (18 years or older) scheduled for elective unilateral carotid endarterectomy at Tampa General Hospital, identified by the treating surgical team from the elective operative schedule and approached during a routine pre-surgical encounter.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adults undergoing elective unilateral carotid endarterectomy at Tampa General Hospital. Continuous bilateral common carotid Doppler signals are recorded intra-operatively at pre-clamp baseline, during internal carotid artery clamping, and at reperfusion, for approximately 20 to 30 minutes in total. Surgical and anesthesia care are not modified, and the recordings are not available to the clinical team.
Device: Bilateral carotid Doppler signal acquisition (Vibrant Stroke Detection Technology)
External, non-invasive recording of common carotid artery flow on both sides of the neck using two legally marketed, FDA-cleared Class II diagnostic ultrasound systems, one per side, each used within its cleared Peripheral Vessel indication: Telemed ArtUs EXT-2H with L12-5N40-A4 transducer (510(k) K211248) and Telemed SmartUs EXT-1M with L15-7L40H-5 transducer (510(k) K163121). Recordings are analyzed offline with Vibrant Medical research software (For Research Use Only). No output is shown to the surgical team and no clinical decision is based on the recordings.
Percentage of Subjects With Successful Bilateral Carotid Signal Acquisition During Baseline and Internal Carotid Artery Clamping
A subject is counted as a success when usable, continuous bilateral common carotid flow signal is acquired for the full duration of Phase 1 (pre-clamp baseline) and Phase 2 (internal carotid artery clamping), adjudicated against signal-quality criteria fixed before the first subject is enrolled. Subjects in whom acquisition fails are retained in the denominator. Reported as the percentage of enrolled subjects with an exact (Clopper-Pearson) 95% confidence interval, against a descriptive benchmark of at least 80%. This is not a hypothesis test. Phase 3 (reperfusion) is not part of this measure.
Time frame: Intra-operative, from pre-clamp baseline through internal carotid artery clamping (single surgical encounter)
Percentage of Subjects With Successful Bilateral Carotid Signal Acquisition During Reperfusion
Usable, continuous bilateral signal acquired for Phase 3, from before internal carotid artery clamp release through 1 to 2 minutes of restored flow. Reported descriptively and separately from the primary outcome, because both transducers are removed during the endarterectomy and re-application depends on not delaying the surgical team.
Time frame: Intra-operative, from before clamp release through 1 to 2 minutes of reperfusion
Carotid Flow Signal Characteristics Time-Locked to Internal Carotid Artery Clamp Application and Release
Signal characteristics, including flow velocity, wave-intensity and bilateral-asymmetry measures, described per subject relative to the documented clamp application and release time stamps, and summarized descriptively. All enrolled subjects with any recorded data are included; no imputation is performed and missing phases are reported as missing.
Time frame: Intra-operative, from pre-clamp baseline through reperfusion (single surgical encounter)
Plan to share: No — Individual participant data are coded, held under the data provisions of the clinical trial agreement, and are not planned for sharing. Aggregate study results will be made publicly available through publication or conference presentation.
No publications or documents are linked to this record.
Start is estimated for Oct 2026; primary completion for Mar 2027, 5 months later.
Of 87 observational studies under Carotid Stenosis, half reached primary completion within 50 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 104. This study's planned 5 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.